Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-10-15
2009-02-17
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010, C514S317000, C514S318000, C514S326000, C544S359000, C544S386000, C546S268100, C546S268400
Reexamination Certificate
active
07491724
ABSTRACT:
The present invention provides compounds of the formula I:its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.
REFERENCES:
patent: 5872152 (1999-02-01), Brown et al.
patent: 5892112 (1999-04-01), Levy et al.
patent: 5968795 (1999-10-01), Dixon et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6436960 (2002-08-01), Shin et al.
patent: 6500847 (2002-12-01), Van Zandt et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 2004/0247606 (2004-12-01), Friedman et al.
patent: 2004/0259896 (2004-12-01), Yao et al.
patent: 2005/0250789 (2005-11-01), Burns et al.
patent: 2007/0117809 (2007-05-01), Fridman
patent: 2007/0280943 (2007-12-01), Friedman et al.
patent: WO 99/65867 (1999-12-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 02/055491 (2002-07-01), None
Xue et al., 1999, CAS: 49888.
Wolfsberg et al.,J. Cell Bio.vol. 131, pp. 275-278 Oct. 25, 1995.
Hooper, 1994,FEBS Lett, vol. 354, pp. 1-6.
Stocker et al., 1995,Curr Opin Struct Biol, vol. 5, pp. 383-390.
Bode et al., 1996,Adv Exp Med Biol, vol. 389, pp. 1-11.
Moscatelli et al., 1988,Biochim Biophys Acta, vol. 948, pp. 67-85.
Parks, 2002,J Clin Invest., vol. 110, pp. 613-614.
Winyard et al., 1991,FEBS Letts, vol. 279, pp. 91-94.
Seals et al., 2003,Genes and Development, vol. 17, pp. 7-30.
Black, 2002,Int J Biochem Cell Biol, vol. 34, pp. 1-5.
Herren et al., 1997,FASEB J., vol. 11, pp. 173-180.
Bohm et al., 1999,Arthritis Rheum, vol. 42, pp. 1946-1950.
Horiuchi et al., 2003,Mol Cell Biol, vol. 23, pp. 5614-5624.
Novak et al., 2001,Curr Opin Immunol, vol. 13, pp. 721-726.
Mayer et al., 2002,Inflamm Res, vol. 51, pp. 85-90.
Yardem et al., 2001,Nature Reviews, vol. 2, pp. 127-137.
Slamon et al., 1987,Science, vol. 235, pp. 177-182.
Rio et al, 2000,J Biol Chem, vol. 275, pp. 10379-10387.
Codony-Servat et al., 1999,Cancer Res, vol. 59, pp. 1196-1201.
Moss et al., 2002,Essays Biochem, vol. 38, pp. 141-153.
Tang, 2001,Int J Biochem Cell Biol, vol. 33, pp. 33-44.
Kaushal et al., 2000,J Clin Invest, vol. 105, pp. 1335-1337.
Levin et al.,Syn. Comm.1982, vol. 12, p. 989.
Wang et al.,J. Org. Chem.1992, vol. 57, p. 6101.
Moss et al., 2001,Drug Discov Today, vol. 6, pp. 417-426.
“Comprehensive Organic Synthesis” (B. M. Trost, I. Fleming, Eds. Pergamon, 1991, vol. 8, Part 1.2, P25, Part 3.1, p. 729.
Gais et al.J. Org. Chem.1989, vol. 54, p. 5115.
Joucla et al.,Chem. Commun. 1985, p. 1566.
Xue et al.,J. Org. Chem. 2002, vol. 67, p. 865.
Jacobsen,Acc. Chem. Res.2000, vol. 33, p. 421.
Combs et al.,Journal of Combinatorial Chemistry2002, vol. 4, p. 179.
Louie,Tetrahedron Lett.1995, vol. 36, p. 3609.
Mishani et. al.Tetrahedron Lett. 1996, vol. 37, p. 319.
Dankwardt et al,Tetrahedron Lett.1995, vol. 36, p. 4923.
Bursavich et al.,Org. Lett.2001, vol. 3, p. 2625.
Burns, D. M. et al., “Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P'1permutations,”Bioorg. Med. Chem. Lett., 2008, 18, 560-564.
Fridman, J.S. et al., “Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB pathways in Cancer”,Clin. Canc. Res., 2007, 13(6), 1892-1901.
Liu, P.C.C. et al., “Indentification of ADAM 10 AS A Major Source of HER-2 Ectodomain Sheddase Activity in HER2 Overexpressing Breast Cancer Cells”,Cancer Biol. Ther., 2006, 5:6, 657-664.
Liu, X. et al., “Selective Inhibition of ADAM Metalloproteases blocks HER-2 Extracellular Domain (ECD) Cleavage and Potentiates the Anti-Tumor Effects of Trastuzumab”,Cancer Biol. Ther., 2006, 5:6, 648-655.
Muller, A.J. and Scherle, P.A., “Targeting the Mechanisms of Tumoral Immune Tolerance with Small-molecule Inhibitors”Nature Rev. Cancer, 2006, 6, 613-626.
Yao, W. et al., “Discovery of Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor of the Treatment of Cancer,”J. Med. Chem.2007, 50, 603-606.
Yao, W., et al., “Design and identification of selective HER-2 sheddase inhibitors via P1'manipulation and unconventional P2'perturbations to induce a molecular metamorphosis”,Bioorg. Med. Chem. Lett., 2008, 18, 159-163.
Zhou, Bin-Bing S. et al., “Targeting ADAM-mediated Ligand Cleavage to Inhibit HER3 and EGFR Pathways in Non-small Cell Lung Cancer”,Cancer Cell, 2006, 10, 39-50.
Zhuo, J., et al., “Asymmetric Synthesis of Conformationally Constrained trans-2,3-Piperidine-Dicarboxylic Acid Derivatives”,SYNLETT, 2007, No. 3, 460-464.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Office Action mailed Jan. 29, 2007 (Restriction Requirement), Examiners Ebenezer O. Sackey and James O. Wilson.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Applicants' Reply filed Feb. 26, 2007 by Applicants' Agent, Christine A. Goodard.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Office Action mailed May 17, 2007 (Non-Final Action), Examiners Ebenezer O. Sackey and James O. Wilson.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Applicant's Amendment filed Aug. 8, 2007 by Applicant's Agent, Christine A. Goodard.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Office Action mailed Oct. 19, 2007 (Ex Parte Quayle Action), Examiners Ebenezer O. Sackey and James O. Wilson.
USPTO file to U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Request for Continued Examination filed Dec. 18, 2007 filed by Applicant's Agent, Christine A. Goodard.
USPTO file of U.S. Appl. No. 10/831,265 (Publ. No. US2004/0259896). Notice of Allowance mailed Mar. 5, 2008, Examiners Ebenezer O. Sackey and James O. Wilson.
Burns David
Jalluri Ravi Kumar
Li Yun-Long
Yao Wenqing
Zhuo Jincong
Fish & Richardson P.C.
Incyte Corporation
Shiao Rei-tsang
LandOfFree
Substituted cyclic hydroxamates as inhibitors of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted cyclic hydroxamates as inhibitors of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted cyclic hydroxamates as inhibitors of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073442